Variables | Univariate | Multivariate 1 | Multivariate 2 | Multivariate 3 | Multivariate 4 | Multivariate 5 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
r | p value | β | p value | β | p value | β | p value | β | p value | β | p value | |
All cases (n = 684) | ||||||||||||
Age | −0.151 | < 0.0001 | −0.104 | 0.008 | −0.125 | 0.001 | −0.134 | 0.001 | −0.144 | 0.0002 | −0.141 | 0.0001 |
Gender | −0.196 | < 0.0001 | −0.135 | 0.0003 | −0.119 | 0.0005 | −0.131 | 0.0007 | −0.113 | 0.003 | −0.079 | 0.027 |
BMI | −0.134 | 0.001 | 0.020 | 0.622 | 0.002 | 0.960 | 0.011 | 0.797 | 0.018 | 0.646 | 0.048 | 0.201 |
Cigarette smoking | −0.054 | 0.163 | ||||||||||
Hypertension | −0.154 | < 0.0001 | −0.014 | 0.707 | −0.009 | 0.814 | −0.019 | 0.630 | −0.024 | 0.527 | −0.008 | 0.822 |
Dyslipidemia | −0.244 | < 0.0001 | −0.047 | 0.311 | −0.082 | −0.068 | −0.084 | 0.087 | −0.052 | 0.266 | −0.010 | 0.819 |
Diabetes mellitus | −0.150 | < 0.0001 | 0.009 | 0.856 | 0.027 | 0.582 | <0.0001 | 0.994 | 0.004 | 0.932 | −0.009 | 0.849 |
HbA1c | −0.131 | 0.0008 | 0.01 | 0.836 | 0.025 | 0.612 | 0.025 | 0.630 | 0.032 | 0.522 | 0.029 | 0.542 |
HDL-C | 0.299 | < 0.0001 | 0.155 | 0.007 | 0.045 | 0.295 | 0.181 | < 0.0001 | 0.236 | < 0.0001 | 0.344 | < 0.0001 |
Statins use | −0.220 | < 0.0001 | −0.131 | 0.003 | −0.109 | 0.010 | −0.138 | 0.003 | −0.108 | 0.014 | −0.147 | 0.0004 |
Fibrates use | −0.122 | 0.002 | −0.075 | 0.037 | −0.059 | 0.088 | −0.081 | 0.029 | 0.069 | 0.052 | −0.063 | 0.061 |
Glitazone use | −0.035 | 0.368 | ||||||||||
TRLs-related markers | ||||||||||||
TG* | −0.446 | < 0.0001 | −0.345 | < 0.0001 | – | – | – | – | ||||
VLDL | −0.502 | < 0.0001 | – | −0.424 | < 0.0001 | – | – | – | ||||
RLP-C* | −0.304 | 0.001 | – | – | −0.240 | < 0.0001 | – | – | ||||
apo C-II | −0.353 | < 0.0001 | – | – | – | −0.323 | < 0.0001 | |||||
apo C-III | −0.401 | < 0.0001 | – | – | – | – | −0.045 | < 0.0001 | ||||
Inflammatory markers | ||||||||||||
WBC count | −0.130 | 0.0007 | −0.036 | 0.339 | −0.031 | 0.387 | −0.053 | 0.170 | −0.065 | 0.082 | −0.035 | 0.318 |
hs-CRP* | −0.110 | 0.005 | 0.002 | 0.956 | −0.018 | 0.636 | 0.008 | 0.843 | 0.014 | 0.720 | 0.026 | 0.472 |
LDL-C < 100 mg.dL (n = 264) | ||||||||||||
Age | −0.095 | 0.124 | ||||||||||
Gender | 0.183 | 0.003 | −0.049 | 0.358 | −0.052 | 0.318 | −0.058 | 0.290 | −0.040 | 0.437 | −0.007 | 0.878 |
BMI | −0.259 | < 0.0001 | −0.065 | 0.258 | −0.076 | 0.174 | −0.074 | 0.210 | −0.044 | 0.426 | −0.019 | 0.723 |
Scigarette smoking | −0.045 | 0.477 | ||||||||||
Hypertension | −0.207 | 0.0008 | −0.033 | 0.562 | −0.042 | 0.448 | −0.035 | 0.555 | −0.024 | 0.656 | −0.025 | 0.625 |
Dyslipidemia | −0.351 | < 0.0001 | −0.151 | 0.042 | −0.189 | 0.009 | −0.187 | 0.017 | −0.162 | 0.023 | −0.098 | 0.149 |
Diabetes mellitus | −0.138 | 0.025 | 0.056 | 0.433 | 0.068 | 0.331 | 0.056 | 0.445 | 0.023 | 0.733 | −0.006 | 0.926 |
HbA1c | −0.154 | 0.013 | −0.025 | 0.732 | −0.037 | 0.598 | −0.017 | 0.820 | 0.014 | 0.839 | −0.001 | 0.987 |
HDL-C | 0.301 | < 0.0001 | 0.055 | 0.347 | −0.002 | 0.969 | 0.131 | 0.026 | 0.213 | 0.0001 | 0.313 | < 0.0001 |
Statins use | −0.193 | 0.002 | 0.005 | 0.937 | −0.002 | 0.970 | −0.038 | 0.583 | 0.007 | 0.917 | −0.049 | 0.416 |
Fibrates use | −0.269 | < 0.0001 | −0.167 | 0.002 | −0.147 | 0.005 | −0.196 | 0.0003 | −0.156 | 0.002 | −0.109 | 0.025 |
Glitazone use | 0.024 | 0.702 | ||||||||||
TRLs-related markers | ||||||||||||
TG* | −0.601 | < 0.0001 | −0.436 | < 0.0001 | – | – | – | – | ||||
VLDL | −0.606 | < 0.0001 | – | −0.464 | < 0.0001 | – | – | – | ||||
RLP-C* | −0.502 | < 0.0001 | – | – | −0.349 | < 0.0001 | – | – | ||||
apo C-II | −0.577 | < 0.0001 | – | – | – | −0.453 | < 0.0001 | – | ||||
apo C-III | −0.591 | < 0.0001 | – | – | – | – | −0.544 | < 0.0001 | ||||
Inflammatory markers | ||||||||||||
WBC count | −0.182 | 0.003 | −0.078 | 0.144 | −0.079 | 0.134 | −0.106 | 0.056 | −0.097 | 0.058 | −0.075 | 0.123 |
hs-CRP* | −0.083 | 0.184 | ||||||||||
Lipid-modifying treatment (n = 335) | ||||||||||||
Age | −0.138 | 0.012 | −0.176 | 0.001 | −0.170 | 0.001 | −0.186 | 0.001 | −0.222 | < 0.0001 | −0.231 | < 0.0001 |
Gender | −0.201 | 0.0002 | −0.176 | 0.002 | −0.143 | 0.008 | −0.162 | 0.006 | −0.166 | 0.003 | −0.131 | 0.014 |
BMI | 0.004 | 0.939 | ||||||||||
Scigarette smoking | −0.036 | 0.510 | ||||||||||
Hypertension | −0.144 | 0.009 | −0.075 | 0.155 | −0.077 | 0.129 | −0.077 | 0.164 | −0.075 | 0.161 | −0.054 | 0.281 |
Dyslipidemia | −0.120 | 0.029 | −0.033 | 0.534 | −0.042 | 0.406 | −0.039 | 0.480 | −0.028 | 0.604 | −0.029 | 0.563 |
Diabetes mellitus | −0.094 | 0.089 | ||||||||||
HbA1c | −0.116 | 0.039 | −0.065 | 0.218 | −0.056 | 0.268 | −0.056 | 0.309 | −0.033 | 0.540 | −0.044 | 0.381 |
HDL-C | 0.220 | < 0.0001 | 0.027 | 0.635 | −0.043 | 0.449 | 0.092 | 0.113 | 0.123 | 0.027 | 0.203 | 0.0002 |
Statins use | 0.019 | 0.731 | ||||||||||
Fibrates use | −0.132 | 0.016 | −0.088 | 0.945 | −0.072 | 0.153 | −0.108 | 0.051 | −0.092 | 0.083 | −0.066 | 0.187 |
Glitazone use | 0.014 | 0.800 | ||||||||||
TRLs-related markers | ||||||||||||
TG* | −0.368 | < 0.0001 | −0.299 | < 0.0001 | – | – | – | – | ||||
VLDL | −0.468 | < 0.0001 | – | −0.424 | < 0.0001 | – | – | – | ||||
RLP-C* | −0.208 | 0.0002 | – | – | −0.133 | 0.019 | – | – | ||||
apo C-II | −0.253 | < 0.0001 | – | – | – | −0.249 | < 0.0001 | – | ||||
apo C-III | −0.384 | < 0.0001 | – | – | – | – | −0.416 | < 0.0001 | ||||
Inflammatory markers | ||||||||||||
WBC count | −0.114 | 0.037 | −0.038 | 0.495 | −0.040 | 0.441 | −0.075 | 0.192 | −0.060 | 0.278 | −0.006 | 0.916 |
hs-CRP* | −0.060 | 0.276 | ||||||||||
No Lipid-modifying treatment (n = 349) | ||||||||||||
Age | −0.105 | 0.051 | ||||||||||
Gender | −0.203 | 0.0002 | −0.073 | 0.163 | −0.063 | 0.218 | −0.072 | 0.178 | −0.036 | 0.282 | −0.008 | 0.867 |
BMI | −0.213 | < 0.0001 | 0.041 | 0.462 | 0.008 | 0.879 | 0.027 | 0.637 | 0.036 | 0.508 | 0.074 | 0.158 |
Scigarette smoking | −0.087 | 0.119 | ||||||||||
Hypertension | −0.084 | 0.121 | ||||||||||
Dyslipidemia | −0.153 | 0.005 | 0.002 | 0.965 | −0.039 | 0.475 | −0.009 | 0.88 | 0.020 | 0.725 | 0.070 | 0.190 |
Diabetes mellitus | −0.116 | 0.032 | −0.03 | 0.575 | 0.006 | 0.916 | −0.047 | 0.405 | −0.040 | 0.451 | −0.005 | 0.267 |
HbA1c | −0.078 | 0.153 | ||||||||||
HDL−C | 0.354 | < 0.0001 | 0.187 | 0.002 | 0.112 | 0.067 | 0.259 | < 0.0001 | 0.349 | < 0.0001 | 0.480 | < 0.0001 |
Glitazone use | −0.046 | 0.392 | ||||||||||
TRLs-related markers | ||||||||||||
TG* | −0.490 | < 0.0001 | −0.420 | < 0.0001 | – | – | – | – | ||||
VLDL | −0.518 | < 0.0001 | – | −0.446 | < 0.0001 | – | – | – | ||||
RLP-C* | −0.408 | < 0.0001 | – | – | −0.355 | < 0.0001 | – | – | ||||
apo C-II | −0.403 | < 0.0001 | – | – | – | −0.417 | < 0.0001 | – | ||||
apo C-III | −0.410 | < 0.0001 | – | – | – | – | −0.528 | < 0.0001 | ||||
Inflammatory markers | ||||||||||||
WBC count | −0.140 | 0.010 | −0.012 | 0.822 | 0.002 | 0.968 | −0.018 | 0.736 | −0.037 | 0.471 | −0.030 | 0.528 |
hs-CRP* | −0.160 | 0.003 | −0.035 | 0.511 | 0.006 | 0.916 | −0.047 | 0.405 | −0.037 | 0.471 | −0.018 | 0.714 |